United States: FDA Proposes To Modify Good Laboratory Practice Regulations, Broaden Application And Authority

On August 24, 2016, the US Food and Drug Administration (FDA) issued a Proposed Rule1 on Good Laboratory Practice for Nonclinical Laboratory Studies (Proposed Rule), which broadens the application and authority of Good Laboratory Practice (GLP) regulations. The Proposed Rule imposes heightened quality requirements for laboratory studies, including safety and toxicity studies, that are intended to support both product applications and other regulatory submissions that are not directly related to product approval. The Proposed Rule also modifies provisions for the care and handling of animals under the so-called Animal Rule and expands requirements to encompass tobacco products. Interested parties have until November 22, 2016, to submit comments, suggestions and feedback.

The Proposed Rule requires the use of a complete quality system approach (GLP Quality System) for nonclinical laboratory studies when such studies support or are intended to support marketing applications or other submissions to FDA.2 FDA proposes to mandate use of a GLP Quality System that is consistent with International Organization for Standardization (ISO) standard ISO 9001:1994, "Quality

Systems—Model for Quality Assurance in Design, Development, Production, Installation and Servicing"; "FDA's Quality System Regulation (QSR)" in 21 CFR Part 820; and wherever possible, Organisation for Economic Co-operation and Development guidance documents for GLP.

Collectively, these standards require tighter controls and procedures for the laboratory Quality Assurance Unit (QAU) and documentation and monitoring of equipment, data and personnel. Among other requirements, FDA proposes to amend provisions related to facility management to specify that the QAU must submit written periodic status reports on GLP Quality System performance for each study to specifically designated management personnel with "executive responsibility" for the facility's operations. The Proposed Rule also imposes new requirements for communication among personnel, internal quality audits, and the creation and documentation of Standard Operating Procedures (SOPs). Notably, FDA proposes to exercise enforcement discretion with respect to the review and evaluation of QAU records by stating that such records will not be subject to routine inspections, but they will be inspected for litigation or during inspections "for cause" under an inspection warrant.

The Proposed Rule also expands the application of Part 58 to efficacy studies conducted on animals under the Animal Rule pathway. Under this pathway, the FDA may grant marketing approval through the use of animal studies to establish the safety and effectiveness of human drugs or biological products when human efficacy studies are unethical or field trials are infeasible (e.g., deliberate exposure of healthy human volunteers to potentially lethal or permanently disabling toxic chemicals). The Proposed Rule differentiates between the types of Animal Rule-specific studies that must adhere to Part 

58, noting that the data quality and integrity requirements are not necessarily appropriate for all types of Animal Rule-specific studies (e.g., studies using challenge agents that require high-containment facilities). The proposed "covered Animal Rule studies" include the adequate and well-controlled efficacy studies that serve as substantial evidence of effectiveness necessary for approval or licensure of human drugs or biological products; pharmacokinetic or pharmacodynamics studies in animals used to select a dose and regimen in humans; and natural history studies to support qualification of new animal models under FDA's Animal Model Qualification Program, the model-defining natural history studies. FDA seeks comment on whether current or proposed requirements pose a unique or disproportionate obstacle or burden on the conduct of certain animal studies specific to product development under the Animal Rule.

In recognition of FDA's authority to regulate tobacco products under the Family Smoking Prevention and Tobacco Control Act of 2009, the Proposed Rule addresses requirements for laboratory studies involving tobacco products. FDA proposes to apply the new GLP requirements to studies designed to "provide evidence regarding the relative toxicities of new or modified risk tobacco products," as specified in sections 905, 910 and 911 of the Federal Food, Drug, and Cosmetic Act (FDCA). The Proposed Rule states that the labeling of a tobacco product may not be used to characterize such a product if it is used as a control or reference article in a nonclinical laboratory study, because labeling of currently marketed tobacco products does not provide the information required for full product characterization, e.g., chemical and microbiological composition or design parameters. FDA plans to issue regulations under section 910(g) of the FDCA, providing conditions under which tobacco products intended for investigational use may be exempted from general tobacco product requirements under the FDCA.

The chart below describes these and other revisions to key provisions of the rule in greater detail. The chart compares selected provisions of Part 58 in its current form with the Proposed Rule and describes potential implications of the changes, in the event any or all of the Proposed Rule's sections are implemented in its final iteration.3

Download >> FDA Proposes to Modify Good Laboratory Practice Regulations, Broaden Application and Authority


1 81 Fed. Reg. 58,342 (Aug. 24, 2016).

2 According to FDA, other submissions include nutrient content and health claim petitions for food, authorizations to market edible animal products, product development protocols for medical devices and data supporting changes to medical device performance standards. See 81 Fed. Reg. 58,367–58,368 (Aug. 24, 2016).

3 Note, the chart does not contain every proposed modification. It excludes certain items, deemed minor or described elsewhere in this document.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions